BMI View: Pakistan remains one of the least attractive markets in the Asia Pacific region to
pharmaceutical and healthcare investment. We project that a lack of government support for
pharmaceutical research and development, and an ineffective regulatory regime, will ..."
BMI View: Healthcare provision in Pakistan continues to lag behind that of neighbouring countries.
Communicable diseases pose substantial problems, and with poor public hygiene, inadequate healthcare
facilities and large numbers of unfilled positions for medical perso ..."
BMI View: Pakistan's government is focused on increasing its pharmaceutical export capacity. However,
we believe it would serve the country's population better if the government invested in improving local
pharmaceutical production capabilities to ensure patient acces ..."
BMI View: It is vital that the Pakistani government enforces regulations to ensure the rational prescription,
dispensing and consumption of medicines. While on one hand medicine affordability levels are low, a study
highlighting irrational drug use in the country is a cause for ..."
BMI View: Increased longevity in developed markets translates into an increased demand for aged care healthcare services and medicines. However, in emerging markets such as Pakistan, despite increased life expectancy, communicable diseases will remain a significant health burden ..."
BMI View: While Pakistan has a substantial population of 174mn people, annual per capita expenditure on pharmaceuticals is very modest, at just US$10 for 2012. Despite expected economic progress, the majority of the population will continue to have inadequate access to medicines ..."
For new medicines to be launched into the Pakistani market, the pharmaceutical regulator must drop its requirement for local rigorous drug approvals and registration process. The country does not have the necessary number of trained professionals to effectively monitor the costly ..."
BMI View: For new medicines to be launched into the Pakistani market, the pharmaceutical
regulator must drop its requirement for local rigorous drug approvals and registration process. The
country does not have the necessary number of trained professionals to effectively monito ..."